Table 3.
Safety and efficacy of ETV and TDF at 48 weeks
| ETV (n = 163) | THF (n = 154) | Total (n = 317) | p value | |
|---|---|---|---|---|
| ΔCholesterol, mg/dL | 6 (–11–22) | –10 (–28.0–8) | 0.00 (–23.00–16.00) | 0.000* |
| AALP, IU/L | –6.00 (–28.33–18.67) | –5.50 (–4.25–28.00) | –6.00 (–31.83–23.33) | 0.580 |
| ΔeGFR, mg/dL | –0.40 (–12.20–6.70) | –3.35 (–16.13–10.70) | –0.60 (–13.30–8.60) | 0.765 |
| Complications of LC, n (%) | 3 (1.8) | 1 (0.7) | 4 (1.1) | 0.114 |
| Varices | 0 (0) | 0 (0) | 0 (0) | |
| Variceal bleeding | 2 (66.7) | 1 (100) | 3 (75) | |
| Ascites | 1 (33.3) | 0 (0) | 1 (25) | |
| SBP | 0 (0) | 0 (0) | 0 (0) | |
| HE | 0 (0) | 0 (0) | 0 (0) | |
| HBeAg seroconversion | 28/97 (26.8%) | 12/80 (15.0%) | 38/177 (21.5%) | 0.057 |
| CVR | 128/163 (78.5%) | 127/154 (82.5%) | 255/317 (80.4%) | 0.377 |
| ALT normalization | 133/162 (82.1%) | 152/117 (77.0%) | 250/314 (79.6%) | 0.260 |
ETV, entecavir; TDF, tenofovir disoproxil fumarate; ALP, alkaline phosphatase; eGFR, estimated glomerular filtration rate; LC, liver cirrhosis; SBP, spontaneous bacterial peritonitis; HE, hepatic encephalopathy; CVR, complete viral response; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen. p < 0.05 is considered statistically significant.